These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 75485)

  • 61. VSV-inhibitor, interferon and anti-interferon activities in subacute and chronic viral infections.
    Stancek D; Táborský I
    Acta Biol Med Ger; 1979; 38(5-6):895-99. PubMed ID: 230680
    [No Abstract]   [Full Text] [Related]  

  • 62. Inhibition of cowpox virus infection in mice by interferon therapy.
    Sypulowa A; Zielińska-Jenczylik J; Skurska Z
    Arch Immunol Ther Exp (Warsz); 1972; 20(6):837-40. PubMed ID: 4664108
    [No Abstract]   [Full Text] [Related]  

  • 63. [Smallpox vaccination with protection by interferon and an interferon inducer].
    Bektemirov TA; Burgasova MP; Kuznetsov VP; Rozina EE; Andzhaparidze OG
    Vopr Virusol; 1980; (1):76-8. PubMed ID: 6158179
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E; Trande P; Grottola A; Buttafoco P; Rebecchi AM; Stroffolini T; Callea F; Merighi A; Camellini L; Zoboli P; Cosenza R; Miglioli L; Loria P; Iori R; Carulli N; Manenti F
    Dig Dis Sci; 1996 Jun; 41(6):1241-7. PubMed ID: 8654159
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits.
    Vilcek J; Sulea IT; Zerebeckyj IL; Yip YK
    J Clin Microbiol; 1980 Jan; 11(1):102-5. PubMed ID: 7354125
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The clinical application of fibroblast interferon--an overview.
    Billiau A
    Med Oncol Tumor Pharmacother; 1984; 1(2):87-96. PubMed ID: 6400034
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release.
    Hersey P; Edwards A; Lewis R; Kemp A; McInnes J
    Clin Exp Immunol; 1982 Apr; 48(1):205-12. PubMed ID: 6177461
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice.
    Billiau A; Heremans H; Ververken D; van Damme J; Carton H; de Somer P
    Arch Virol; 1981; 68(1):19-25. PubMed ID: 6166278
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differences between human alpha (leukocyte) and beta (fibroblast) interferons.
    Hayes TG
    Arch Virol; 1981; 67(4):267-81. PubMed ID: 6165341
    [No Abstract]   [Full Text] [Related]  

  • 70. Interferon therapy: pharmacokinetic and pharmacological aspects.
    Billiau A
    Arch Virol; 1981; 67(2):121-33. PubMed ID: 6163417
    [No Abstract]   [Full Text] [Related]  

  • 71. Spontaneous production of human interferon.
    Pickering LA; Kronenberg LH; Stewart WE
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):5938-42. PubMed ID: 6160588
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Attempted treatment of fulminant viral hepatitis with human fibroblast interferon.
    Milazzo F; Galli M; Fassio PG; Cargnel A; Pugliese A; Tovo PA; Vigevani GM; Esposito R; Lazzarin A; Caredda F
    Infection; 1985; 13(3):130-3. PubMed ID: 3897068
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessment of the antigenic response in humans to a recombinant mutant interferon beta.
    Konrad MW; Childs AL; Merigan TC; Borden EC
    J Clin Immunol; 1987 Sep; 7(5):365-75. PubMed ID: 3308943
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction and measurement of 2',5'-oligoadenylate synthetase in Madin-Darby bovine kidney cells and in cattle.
    Short EC; Fulton RW
    J Clin Microbiol; 1987 Sep; 25(9):1735-40. PubMed ID: 2443533
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.
    Billiau A; De Somers P; Edy VG; De Clercq E; Heremans H
    Antimicrob Agents Chemother; 1979 Jul; 16(1):56-63. PubMed ID: 475375
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiviral agents: action and clinical use.
    Chang TW; Snydman DR
    Drugs; 1979 Nov; 18(5):354-76. PubMed ID: 92398
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Non-appearance of injected fibroblast interferon in circulation.
    Edy VG; Billiau A; De Somer P
    Lancet; 1978 Feb; 1(8061):451-2. PubMed ID: 75485
    [No Abstract]   [Full Text] [Related]  

  • 78. Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon.
    Weimar W; Stitz L; Billiau A; Cantell K; Schellekens H
    J Gen Virol; 1980 May; 48(1):25-30. PubMed ID: 6155433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of rates of clearance of human fibroblast and leukocyte interferon from the circulatory system of rabbits.
    Edy VG; Billiau A; De Somer P
    J Infect Dis; 1976 Jun; 133 Suppl():A18-21. PubMed ID: 932502
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Circulating interferon in rabbits after administration of human interferon by different routes.
    Cantell K; Pyhälä L
    J Gen Virol; 1973 Jul; 20(1):97-104. PubMed ID: 4356685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.